Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) Director Timothy A. Springer bought 300,000 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The shares were acquired at an average price of $33.59 per share, for a total transaction of $10,077,000.00. Following the completion of the transaction, the director now directly owns 4,096,764 shares in the company, valued at approximately $137,610,302.76. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Tectonic Therapeutic Stock Performance
NASDAQ TECX traded up $1.89 on Thursday, reaching $36.40. 81,908 shares of the company’s stock traded hands, compared to its average volume of 42,518. Tectonic Therapeutic has a fifty-two week low of $12.12 and a fifty-two week high of $37.99. The business has a 50 day moving average of $24.38. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of 51.17 and a beta of 2.63.
Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($3.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($1.85). On average, analysts expect that Tectonic Therapeutic will post -4.91 EPS for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Report on Tectonic Therapeutic
Institutional Trading of Tectonic Therapeutic
Institutional investors and hedge funds have recently modified their holdings of the stock. Affinity Asset Advisors LLC purchased a new stake in shares of Tectonic Therapeutic during the second quarter worth about $961,000. Renaissance Technologies LLC acquired a new position in Tectonic Therapeutic during the second quarter worth about $1,466,000. Acadian Asset Management LLC acquired a new position in Tectonic Therapeutic during the second quarter worth about $1,804,000. Atlas Venture Life Science Advisors LLC acquired a new position in Tectonic Therapeutic during the second quarter worth about $6,233,000. Finally, Farallon Capital Management LLC acquired a new position in Tectonic Therapeutic during the second quarter worth about $7,099,000. Hedge funds and other institutional investors own 62.63% of the company’s stock.
About Tectonic Therapeutic
Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.
Recommended Stories
- Five stocks we like better than Tectonic Therapeutic
- CD Calculator: Certificate of Deposit Calculator
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Why Invest in 5G? How to Invest in 5G Stocks
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.